学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

陸彦（ルーエン）

研究テーマ	前立腺がんにおけるAhr遺伝子の機能解析およびがん治療への応用研究
研究業績（論文）	1.　Lu Y, Toma C, Honma Y, Iwanaga M. Detection of EspB using reversed passive latex agglutination: application to determination of enteropathogenic Escherichia coli. Diagn Mi　crobiol Infect Dis. 2002;43(1):7-12. 2.　Toma C, Lu Y, Higa N, et al. Multiplex PCR assay for identification of human diarrheagenic Escherichia coli. J Clin Microbiol. 2003;41(6):2669-2671. 3.　Iyoda S, Koizumi N, Satou H, et al. The GrlR-GrlA regulatory system coordinately controls the expression of flagellar and LEE-encoded type III protein secretion systems in enterohemorrhagic Escherichia coli. J Bacteriol. 2006;188(16):5682-5692. 4.　Lu Y, Iyoda S, Satou H, et al. A new immunoglobulin-binding protein, EibG, is responsible for the chain-like adhesion phenotype of locus of enterocyte effacement-negative, shiga toxin-producing Escherichia coli. Infect Immun. 2006;74(10):5747-5755. 5.Nakasone N, Toma C, Lu Y, Iwanaga M. Development of a rapid immunochromatographic test to identify enteropathogenic and enterohemorrhagic Escherichia coli by detecting EspB. Diagn Microbiol Infect Dis. 2007;57(1):21-25. 6.　Saitoh T, Iyoda S, Yamamoto S, et al. Transcription of the ehx enterohemolysin gene is positively regulated by GrlA, a global regulator encoded within the locus of enterocyte effacement in enterohemorrhagic Escherichia coli. J Bacteriol. 2008;190(14):4822-4830. 7.　Ide H, Yu J, Lu Y, et al. Testosterone augments polyphenol-induced DNA damage response in prostate cancer cell line, LNCaP. Cancer Sci. 2011;102(2):468-471. 8.　Aoki H, Nagao J, Ueda T, et al. Clinical assessment of a supplement of Pycnogenol(R) and L-arginine in Japanese patients with mild to moderate erectile dysfunction. Phytother Res. 2012;26(2):204-207. 9.　Ide H, Lu Y, Yu J, et al. Testosterone promotes DNA damage response under oxidative stress in prostate cancer cell lines. Prostate. 2012;72(13):1407-1411. 10.　Ide H, Terado Y, Sakamaki K, et al. Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer. Prostate Int. 2013;1(3):109-112. 11.　Ide H, Lu Y, Tanaka T, et al. Circulating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot study. Prostate Int. 2014;2(3):147-151. 12.　Ide H, Yamagishi S, Lu Y, et al. Circulating pigment epithelium-derived factor (PEDF) is associated with pathological grade of prostate cancer. Anticancer Res. 2015;35(3):1703-1708. 13.　Kawano H, Muto S, Ohmoto Y, et al. Exploring urinary biomarkers in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2015;19(5):968-973. 14.　Nakajima A, Lu Y, Kawano H, Horie S, Muto S. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD). Clin Exp Nephrol. 2015;19(6):1199-1205. 15.　Ide H, Lu Y, Yu J, et al. Aryl hydrocarbon receptor signaling involved in the invasiveness of LNCaP cells. Hum Cell. 2017;30(2):133-139. 16.　Mizuno T HI, Aoki Y, Shimoyama H, Nozaki T, Shirai M, Lu Y, Horie S, Tsujimura A. Relation between histological prostatitis and lower urinary tract symptoms and erectile function. Prostate International. 2017;5(3):5. 17.　Hou Q, Bing ZT, Hu C, et al. RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer. EBioMedicine. 2018;32:234-244. 18.　Ide H, Lu Y, Noguchi T, et al. Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer. Cancer Sci. 2018;109(4):1230-1238. 19.　Ide H, Lu Y, Ono M, Tokairin T, Okada H, Horie S. Intra-adrenal corticotropin in bilateral macronodular adrenal hyperplasia: Report of two Japanese cases. Int J Urol. 2018;25(3):307-308. 20.　Inoue Y, Nakamura K, Kuwahara Y, et al. Efficacy of Testosterone Treatment in Hemodialysis Patients as Assessed by Aging Males' Symptoms Scores: A Pilot Study. Am J Mens Health. 2018;12(5):1541-1547. 21.　De Velasco MA, Lu Y, Kura Y, et al. Chemopreventive effects of nanoparticle curcumin in a mouse model of Pten-deficient prostate cancer. Hum Cell. 2020;33(3):730-736. 22.　Hirano H, Ide H, Lu Y, Inoue Y, Okada H, Horie S. Impact of Pretreatment Total Cholesterol Level Is Associated With Metastasis of Prostate Cancer. Am J Mens Health. 2020;14(2):1557988320918788. 23.　Nagaya N, Nagata M, Lu Y, et al. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLoS One. 2020;15(1):e0226219. 24.　Yu J, Lu Y, Muto S, Ide H, Horie S. The Dual Function of Aryl Hydrocarbon Receptor in Bladder Carcinogenesis. Anticancer Res. 2020;40(3):1345-1357. 25.　Muto S, Lu Y, Ide H, et al. The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non–muscle‑invasive Bladder Cancer. European Urology Open Science. 2021;27:10-18. 26.　Nagaya N, Lee GT, Lu Y, et al. Transcription factor 4 expression in circulating tumor cells from castration-resistant prostate cancer. IJU Case Rep. 2021;4(3):159-162. 27.　Nakayama A, Ide H, Lu Y, et al. Effects of Curcumin Combined With the 5-alpha Reductase Inhibitor Dutasteride on LNCaP Prostate Cancer Cells. In Vivo. 2021;35(3):1443-1450. 28.　Ashizawa T, Nagata M, Nakamura S, et al. Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer. Sci Rep. 2022;12(1):18016. 29. Ide H, Tsukada S, Asakura H, et al. A Japanese Box Lunch Bento Comprising Functional Foods Reduce Oxidative Stress in Men: A Pilot Study. Am J Mens Health. 2022;16(1):15579883221075498. 30. Wei Y, Kobayashi T, Lu Y, et al. Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score-matching Study. Eur Urol Open Sci. 2022;46:88-95. 31. Chen R, Lu Y, Horie S, et al. Cancer-directed surgery brings survival benefits for patients with advanced prostate cancer: a population-based propensity-score matching study. J Cancer. 2023;14(2):231-238. 32.　Chen S, Song W, Zhang R, et al. Analysis of survival and prognostic factors of clear cell adenocarcinoma of the prostate: a case-control study for a rare cancer entity. Sci Rep. 2023;13(1):10317. 33.　Hirano H, Nagata M, Nagaya N, et al. Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases. Sci Rep. 2023;13(1):8704. 34.　Kimura T, Kawano H, Muto S, et al. PKD1 Mutation Is a Biomarker for Autosomal Dominant Polycystic Kidney Disease. Biomolecules. 2023;13(7). 35.Wu W, Zhang R, Jin Y, et al. Cancer trends and risk factors in China over the past 30 years (1990-2019). J Cancer. 2023;14(10):1935-1945. 36.Kobayashi T, Nagata M, Hachiya T, et al. Increased circulating polymorphonuclear myeloid-derived suppressor cells are associated with prognosis of metastatic castration-resistant prostate cancer. Front Immunol. 2024;15:1372771. 37.　Nakamura S, Nagata M, Nagaya N, et al. The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide. Cancers (Basel). 2024;16(4). 38.　Shirakawa T, Fink J, Hotta ZU, et al. The impact of serum testosterone level to reflect age-related multi-organ functions. Endocr J. 2024. 39.Wakita H, Lu Y, Li X, et al. Evaluating Leukocyte Telomere Length and Myeloid-Derived Suppressor Cells as Biomarkers for Prostate Cancer. Cancers (Basel). 2024;16(7). 40. 　Pengfeng Gong, Hisamitsu Ide, Yan Lu , Masayoshi Nagata , Tomoki Kimura , Toshiyuki China , Ippei Hiramatsu, Takuro Kobayashi, Yoshihiro Ikehata, Jun Zhou and Shigeo Horie. Prostate-Specific Antigen Decline Rate in the First Month Is a Timely Predictive Factor for Biochemical Recurrence After Robot-Assisted Radical Prostatectomy. Cancers 2025, 17(6), 961; https://doi.org/10.3390/cancers17060961 41. 　Takuro Kobayashi, Tsuyoshi Hachiya, Yan Lu, Yoshihiro Ikehata, Toshiyuki China, Haruna Kawano, Masayoshi Nagata, Hisamitsu Ide, Shuji Isotani, Shuko Nojiri, Takuro Iwami, Shunsuke Uchiyama, Yasushi Okazaki, Hidewaki Nakagawa, Takayuki Morisaki, Koichi Matsuda, Yoichiro Kamatani, Chikashi Terao & Shigeo Horie. Local radiotherapy for cancer patients is associated with mosaic loss of chromosome Y, a hallmark of male aging. npj Aging volume 11, Article number: 69 (2025). 42. 　Yiming Jin, Hisamitsu Ide, Masayoshi Nagata, Takuro Kobayashi, Jun Lu, Yoshihiro Ikehata, Fumitaka Shimizu, Yan Lu, Shigeo Horie. Pre-treatment monocytic myeloid-derived suppressor cells as predictive biomarkers for immune checkpoint inhibitor response in clear cell renal cell carcinoma. Front. Immunol., 21 August 2025. Sec. Cancer Immunity and Immunotherapy.Volume 16 - 2025 \| https://doi.org/10.3389/fimmu.2025.1641383

研究テーマ

前立腺がんにおけるAhr遺伝子の機能解析およびがん治療への応用研究

研究業績（論文）

1.　Lu Y, Toma C, Honma Y, Iwanaga M. Detection of EspB using reversed passive latex agglutination: application to determination of enteropathogenic Escherichia coli. Diagn Mi　crobiol Infect Dis. 2002;43(1):7-12.
2.　Toma C, Lu Y, Higa N, et al. Multiplex PCR assay for identification of human diarrheagenic Escherichia coli. J Clin Microbiol. 2003;41(6):2669-2671.
3.　Iyoda S, Koizumi N, Satou H, et al. The GrlR-GrlA regulatory system coordinately controls the expression of flagellar and LEE-encoded type III protein secretion systems in enterohemorrhagic Escherichia coli. J Bacteriol. 2006;188(16):5682-5692.
4.　Lu Y, Iyoda S, Satou H, et al. A new immunoglobulin-binding protein, EibG, is responsible for the chain-like adhesion phenotype of locus of enterocyte effacement-negative, shiga toxin-producing Escherichia coli. Infect Immun. 2006;74(10):5747-5755.
5.Nakasone N, Toma C, Lu Y, Iwanaga M. Development of a rapid immunochromatographic test to identify enteropathogenic and enterohemorrhagic Escherichia coli by detecting EspB. Diagn Microbiol Infect Dis. 2007;57(1):21-25.
6.　Saitoh T, Iyoda S, Yamamoto S, et al. Transcription of the ehx enterohemolysin gene is positively regulated by GrlA, a global regulator encoded within the locus of enterocyte effacement in enterohemorrhagic Escherichia coli. J Bacteriol. 2008;190(14):4822-4830.
7.　Ide H, Yu J, Lu Y, et al. Testosterone augments polyphenol-induced DNA damage response in prostate cancer cell line, LNCaP. Cancer Sci. 2011;102(2):468-471.
8.　Aoki H, Nagao J, Ueda T, et al. Clinical assessment of a supplement of Pycnogenol(R) and L-arginine in Japanese patients with mild to moderate erectile dysfunction. Phytother Res. 2012;26(2):204-207.
9.　Ide H, Lu Y, Yu J, et al. Testosterone promotes DNA damage response under oxidative stress in prostate cancer cell lines. Prostate. 2012;72(13):1407-1411.
10.　Ide H, Terado Y, Sakamaki K, et al. Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer. Prostate Int. 2013;1(3):109-112.
11.　Ide H, Lu Y, Tanaka T, et al. Circulating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot study. Prostate Int. 2014;2(3):147-151.
12.　Ide H, Yamagishi S, Lu Y, et al. Circulating pigment epithelium-derived factor (PEDF) is associated with pathological grade of prostate cancer. Anticancer Res. 2015;35(3):1703-1708.
13.　Kawano H, Muto S, Ohmoto Y, et al. Exploring urinary biomarkers in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2015;19(5):968-973.
14.　Nakajima A, Lu Y, Kawano H, Horie S, Muto S. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD). Clin Exp Nephrol. 2015;19(6):1199-1205.
15.　Ide H, Lu Y, Yu J, et al. Aryl hydrocarbon receptor signaling involved in the invasiveness of LNCaP cells. Hum Cell. 2017;30(2):133-139.
16.　Mizuno T HI, Aoki Y, Shimoyama H, Nozaki T, Shirai M, Lu Y, Horie S, Tsujimura A. Relation between histological prostatitis and lower urinary tract symptoms and erectile function. Prostate International. 2017;5(3):5.
17.　Hou Q, Bing ZT, Hu C, et al. RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer. EBioMedicine. 2018;32:234-244.
18.　Ide H, Lu Y, Noguchi T, et al. Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer. Cancer Sci. 2018;109(4):1230-1238.
19.　Ide H, Lu Y, Ono M, Tokairin T, Okada H, Horie S. Intra-adrenal corticotropin in bilateral macronodular adrenal hyperplasia: Report of two Japanese cases. Int J Urol. 2018;25(3):307-308.
20.　Inoue Y, Nakamura K, Kuwahara Y, et al. Efficacy of Testosterone Treatment in Hemodialysis Patients as Assessed by Aging Males' Symptoms Scores: A Pilot Study. Am J Mens Health. 2018;12(5):1541-1547.
21.　De Velasco MA, Lu Y, Kura Y, et al. Chemopreventive effects of nanoparticle curcumin in a mouse model of Pten-deficient prostate cancer. Hum Cell. 2020;33(3):730-736.
22.　Hirano H, Ide H, Lu Y, Inoue Y, Okada H, Horie S. Impact of Pretreatment Total Cholesterol Level Is Associated With Metastasis of Prostate Cancer. Am J Mens Health. 2020;14(2):1557988320918788.
23.　Nagaya N, Nagata M, Lu Y, et al. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLoS One. 2020;15(1):e0226219.
24.　Yu J, Lu Y, Muto S, Ide H, Horie S. The Dual Function of Aryl Hydrocarbon Receptor in Bladder Carcinogenesis. Anticancer Res. 2020;40(3):1345-1357.
25.　Muto S, Lu Y, Ide H, et al. The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guérin Therapy in Patients with Non–muscle‑invasive Bladder Cancer. European Urology Open Science. 2021;27:10-18.
26.　Nagaya N, Lee GT, Lu Y, et al. Transcription factor 4 expression in circulating tumor cells from castration-resistant prostate cancer. IJU Case Rep. 2021;4(3):159-162.
27.　Nakayama A, Ide H, Lu Y, et al. Effects of Curcumin Combined With the 5-alpha Reductase Inhibitor Dutasteride on LNCaP Prostate Cancer Cells. In Vivo. 2021;35(3):1443-1450.
28.　Ashizawa T, Nagata M, Nakamura S, et al. Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer. Sci Rep. 2022;12(1):18016.
29. Ide H, Tsukada S, Asakura H, et al. A Japanese Box Lunch Bento Comprising Functional Foods Reduce Oxidative Stress in Men: A Pilot Study. Am J Mens Health. 2022;16(1):15579883221075498.
30. Wei Y, Kobayashi T, Lu Y, et al. Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score-matching Study. Eur Urol Open Sci. 2022;46:88-95.
31. Chen R, Lu Y, Horie S, et al. Cancer-directed surgery brings survival benefits for patients with advanced prostate cancer: a population-based propensity-score matching study. J Cancer. 2023;14(2):231-238.
32.　Chen S, Song W, Zhang R, et al. Analysis of survival and prognostic factors of clear cell adenocarcinoma of the prostate: a case-control study for a rare cancer entity. Sci Rep. 2023;13(1):10317.
33.　Hirano H, Nagata M, Nagaya N, et al. Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases. Sci Rep. 2023;13(1):8704.
34.　Kimura T, Kawano H, Muto S, et al. PKD1 Mutation Is a Biomarker for Autosomal Dominant Polycystic Kidney Disease. Biomolecules. 2023;13(7).
35.Wu W, Zhang R, Jin Y, et al. Cancer trends and risk factors in China over the past 30 years (1990-2019). J Cancer. 2023;14(10):1935-1945.
36.Kobayashi T, Nagata M, Hachiya T, et al. Increased circulating polymorphonuclear myeloid-derived suppressor cells are associated with prognosis of metastatic castration-resistant prostate cancer. Front Immunol. 2024;15:1372771.
37.　Nakamura S, Nagata M, Nagaya N, et al. The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide. Cancers (Basel). 2024;16(4).
38.　Shirakawa T, Fink J, Hotta ZU, et al. The impact of serum testosterone level to reflect age-related multi-organ functions. Endocr J. 2024.
39.Wakita H, Lu Y, Li X, et al. Evaluating Leukocyte Telomere Length and Myeloid-Derived Suppressor Cells as Biomarkers for Prostate Cancer. Cancers (Basel). 2024;16(7).
40. 　Pengfeng Gong, Hisamitsu Ide, Yan Lu , Masayoshi Nagata , Tomoki Kimura , Toshiyuki China ,
Ippei Hiramatsu, Takuro Kobayashi, Yoshihiro Ikehata, Jun Zhou and Shigeo Horie. Prostate-Specific Antigen Decline Rate in the First Month Is a Timely Predictive Factor for Biochemical Recurrence After Robot-Assisted Radical Prostatectomy. Cancers 2025, 17(6), 961; https://doi.org/10.3390/cancers17060961
41. 　Takuro Kobayashi, Tsuyoshi Hachiya, Yan Lu, Yoshihiro Ikehata, Toshiyuki China, Haruna Kawano, Masayoshi Nagata, Hisamitsu Ide, Shuji Isotani, Shuko Nojiri, Takuro Iwami, Shunsuke Uchiyama, Yasushi Okazaki, Hidewaki Nakagawa, Takayuki Morisaki, Koichi Matsuda, Yoichiro Kamatani, Chikashi Terao & Shigeo Horie. Local radiotherapy for cancer patients is associated with mosaic loss of chromosome Y, a hallmark of male aging. npj Aging volume 11, Article number: 69 (2025).
42. 　Yiming Jin, Hisamitsu Ide, Masayoshi Nagata, Takuro Kobayashi, Jun Lu, Yoshihiro Ikehata, Fumitaka Shimizu, Yan Lu, Shigeo Horie. Pre-treatment monocytic myeloid-derived suppressor cells as predictive biomarkers for immune checkpoint inhibitor response in clear cell renal cell carcinoma. Front. Immunol., 21 August 2025. Sec. Cancer Immunity and Immunotherapy.Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1641383

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

陸 彦（ルー エン）

陸彦（ルーエン）